Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CA 125

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    523 result(s) found for: CA 125. Displaying page 1 of 27.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-003580-31 Sponsor Protocol Number: MORAb-003-002 Start Date*: 2007-04-23
    Sponsor Name:Morphotek
    Full Title: A Study of the Efficacy of MORAb-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
    Medical condition: Ovarian cancer in first relapse
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-003089-16 Sponsor Protocol Number: AGO-OVAR2.11 Start Date*: 2007-08-31
    Sponsor Name:AGO Research GmbH
    Full Title: Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine k...
    Medical condition: Platinum refractory or resistant ovarian cancer, primary cancer of the peritoneum or fallopian tube (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002668-32 Sponsor Protocol Number: OAS-07OVA Start Date*: 2009-04-16
    Sponsor Name:Oasmia Pharmaceutical AB
    Full Title: An Open, Randomized, Multicenter Study in Patients with Recurrent Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficacy and Safety of paclitaxel (mic...
    Medical condition: Histological or cytological confirmed epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) BE (Completed) CZ (Completed) HU (Completed) LV (Completed) SK (Completed) LT (Completed) DK (Completed) BG (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-002483-27 Sponsor Protocol Number: PKB116611 Start Date*: 2012-11-07
    Sponsor Name:Accenture
    Full Title: An Open-Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with Platinum-Resistant Ovarian Cancer
    Medical condition: Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002836-10 Sponsor Protocol Number: C3291002 Start Date*: 2019-08-22
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 4, Multicenter, Open Label Safety Study Of Crisaborole Ointment 2% In Children Aged 3 Months To Less Than 24 Months With Mild To Moderate Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001472-10 Sponsor Protocol Number: INCB24360-210 Start Date*: 2012-10-19
    Sponsor Name:Incyte Corporation
    Full Title: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 VERSUS TAMOXIFEN FOR SUBJECTS WITH BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FAL...
    Medical condition: BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CANCER FOLLOWING COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003384-30 Sponsor Protocol Number: IR902-231 Start Date*: 2007-02-26
    Sponsor Name:The Immune Response Corporation
    Full Title: A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001552-44 Sponsor Protocol Number: TRIO 015 Start Date*: 2008-09-29
    Sponsor Name:Cancer International research Group
    Full Title: A MULTICENTER OPEN LABEL PHASE II STUDY OF THE EFFICACY AND SAFETY OF AMG 479, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST INSULIN-LIKE GROWTH FACTOR TYPE 1 RECEPTOR (IGF-1R) AS SECOND LINE THERAPY I...
    Medical condition: Recurrent Platinum-sensitive ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) DE (Completed) ES (Prematurely Ended) IE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006979-72 Sponsor Protocol Number: C14006 Start Date*: 2009-04-14
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal ...
    Medical condition: Platinum-refractory and platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    11.1 10033131 LLT
    11.1 10016180 LLT
    11.1 10052171 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001642-10 Sponsor Protocol Number: SMT19969/C005 Start Date*: 2019-03-13
    Sponsor Name:Summit (Oxford) Limited
    Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ...
    Medical condition: Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) LT (Completed) BE (Prematurely Ended) DE (Completed) CZ (Completed) ES (Ongoing) FR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001641-27 Sponsor Protocol Number: SMT19969/C004 Start Date*: 2019-07-05
    Sponsor Name:Summit (Oxford) Limited
    Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ...
    Medical condition: Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GR (Prematurely Ended) BG (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-007497-37 Sponsor Protocol Number: GINECO-OV214 Start Date*: 2009-01-28
    Sponsor Name:ARCAGY
    Full Title: ESSAI EN DEUX ETAPES DE L’EVALUATION DE LA LENALIDOMIDE (REVLIMID®) DANS LE CANCER DE L’OVAIRE EN RECHUTE TARDIVE (> 6 MOIS): - EN MONOTHERAPIE CHEZ DES PATIENTES ASYMPTOMATIQUES AVEC UNE ELEVATIO...
    Medical condition: Ovarian cancer patients in late relapse
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000446-19 Sponsor Protocol Number: 1720302 Start Date*: 2018-11-30
    Sponsor Name:Revance Therapeutics Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults ...
    Medical condition: Cervical Dystonia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10064124 Cervical dystonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PL (Completed) FR (Completed) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000557-30 Sponsor Protocol Number: BO17931 Start Date*: 2005-10-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase II, open- label, controlled, randomized, multicenter study to evaluate the efficacy and safety of pertuzumab (Omnitarg™), a recombinant humanized antibody against HER2, in combination with...
    Medical condition: Platinum sensitive recurrent ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005686-20 Sponsor Protocol Number: 004 Start Date*: 2012-08-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients ...
    Medical condition: Patients with Complicated Intra-Abdominal Infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) PT (Completed) GR (Completed) LT (Completed) LV (Completed) EE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003466-34 Sponsor Protocol Number: M06OVH Start Date*: 2006-12-14
    Sponsor Name:NKI-AVL
    Full Title: Phase III randomised clinical trial for stage III ovarian carcinoma randomising between secondary debulking surgery with or without hyperthermic intraperitoneal chemotherapy (OVHIPEC-I)
    Medical condition: ovarian carcinoma or peritoneal cancer (PPSC) or fallopian tube carcinoma FIGO Stage III
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003323-20 Sponsor Protocol Number: CP4055-204 Start Date*: 2008-05-30
    Sponsor Name:Clavis Pharma ASA
    Full Title: A Phase I/II Study of CP-4055 in Patients with Platinum Resistant Ovarian Cancer
    Medical condition: A phase I/II clinical study of CP4055 in patients with platinum resistant ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000825-18 Sponsor Protocol Number: CSET2020/3047 Start Date*: 2020-05-12
    Sponsor Name:Gustave Roussy
    Full Title: An open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNATM, a DNA repair inhibitor, administered intravenously in addition to Niraparib in patients with relapsed p...
    Medical condition: Relapsed platinum sensitive ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002738-36 Sponsor Protocol Number: AKST4290-205 Start Date*: 2019-10-30
    Sponsor Name:Alkahest, Inc.
    Full Title: A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 with Loading Doses of Aflibercept in Patients with Newly Diagnosed Neovascular Age-Related Macular ...
    Medical condition: Newly Diagnosed Neovascular Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2023-000946-41 Sponsor Protocol Number: VX19-809-124 Start Date*: 2023-10-17
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Open-label, and Rollover Study to Evaluate the Long-term Safety and Tolerability of Lumacaftor/Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 ...
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:12:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA